AIDS · 2000 · 33 citations · 10 references
PharmacyPharmacotherapyClinical PharmacologyHiv ControlPharmacovigilanceAntiretroviral TherapyAntiviral AgentsAntiviral TherapyMedication AdherencePatient AdherenceTreatment AdherenceAdherence In Hiv TreatmentAntiretroviral Therapy CoverageClinical Outcome MeasurementHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyTriple Combination TherapyVirological Diagnosis
OBJECTIVE: To compare adherence and clinical outcome with two modalities of highly active antiretroviral therapy (HAART), in HIV-infected patients. DESIGN: Randomized, open-label, prospective study. SETTING: Tertiary care centre in Spain. PATIENTS: A total of 112 non-naive HIV-infected patients, recruited from March 1998 through August 1998, were studied. INTERVENTIONS: Triple drug therapy with stavudine and lamivudine, plus indinavir or nelfinavir. MAIN OUTCOME MEASURES: Adherence, side-effects, and immunological, virological, and clinical efficacy of treatment were assessed at 3-month intervals. RESULTS: After a median follow-up of 9 months, 32% of patients in the indinavir group versus 50% of those in the nelfinavir group showed adequate adherence in all clinical appointments (P= 0.0559). Adherence was superior in the nelfinavir group in every visit. After 6 months of treatment 48% of subjects in the indinavir group and 70% of those in the nelfinavir group exhibited adequate adherence (P= 0.0311). After 9 months 35% of patients in the indinavir group and 59% of those in the nelfinavir group showed adequate adherence (P= 0.0291). Side-effects provoked discontinuation of treatment in 34% of patients in the indinavir group and 12% of patients in the nelfinavir group (P= 0.0073). Immunological and virological efficacy were similar in both groups. CONCLUSIONS: Adherence to a HAART regimen with stavudine plus lamivudine plus nelfinavir was superior to a regimen with stavudine plus lamivudine plus indinavir. Side-effects provoked more discontinuation of treatment in the indinavir group than in the nelfinavir group.
10
Antiretroviral Therapy for HIV Infection in 1997
Charles C. J. Carpenter · JAMA · 1997 · 730 citations
Self-reported Antiretroviral Therapy in Injection Drug Users
David D. Celentano · JAMA · 1998 · 272 citations
Public Health, Infectious Disease Control, Pharmacotherapy +15